Tvardi Therapeutics (TVRD)
NASDAQ:TVRD
Total Valuation
Tvardi Therapeutics has a market cap or net worth of $28.33M. The enterprise value is $7.80M.
Market Cap$28.33M
Enterprise Value$7.80M
Share Statistics
Tvardi Therapeutics has 9,381,344 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding9,381,344
Owned by Insiders12.88%
Owned by Institutions12.51%
Financial Efficiency
Tvardi Therapeutics’s return on equity (ROE) is -0.87 and return on invested capital (ROIC) is -126.49%.
Return on Equity (ROE)-0.87
Return on Assets (ROA)-0.57
Return on Invested Capital (ROIC)-126.49%
Return on Capital Employed (ROCE)-1.27
Revenue Per Employee0.00
Profits Per Employee-1.07M
Employee Count17
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Tvardi Therapeutics is ―. Tvardi Therapeutics’s PEG ratio is 0.02.
PE Ratio―
PS Ratio0.00
PB Ratio1.52
Price to Fair Value1.52
Price to FCF-1.36
Price to Operating Cash Flow-1.16
PEG Ratio0.02
Income Statement
In the last 12 months, Tvardi Therapeutics had revenue of 0.00 and earned -18.21M in profits. Earnings per share was -2.46.
Revenue0.00
Gross Profit0.00
Operating Income-26.75M
Pretax Income-18.21M
Net Income-18.21M
EBITDA-26.65M
Earnings Per Share (EPS)-2.46
Cash Flow
In the last 12 months, operating cash flow was -23.50M and capital expenditures 0.00, giving a free cash flow of -23.50M billion.
Operating Cash Flow-23.50M
Free Cash Flow-23.50M
Free Cash Flow per Share-2.50
Dividends & Yields
Tvardi Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.25
52-Week Price Change-79.03%
50-Day Moving Average3.76
200-Day Moving Average14.36
Relative Strength Index (RSI)31.42
Average Volume (3m)401.55K
Important Dates
Tvardi Therapeutics upcoming earnings date is May 19, 2026, TBA (Confirmed).
Last Earnings DateMar 31, 2026
Next Earnings DateMay 19, 2026
Ex-Dividend Date―
Financial Position
Tvardi Therapeutics as a current ratio of 2.86, with Debt / Equity ratio of 0.96%
Current Ratio2.86
Quick Ratio2.86
Debt to Market Cap0.00
Net Debt to EBITDA0.77
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Tvardi Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Tvardi Therapeutics EV to EBITDA ratio is -0.43, with an EV/FCF ratio of -0.48.
EV to Sales0.00
EV to EBITDA-0.43
EV to Free Cash Flow-0.48
EV to Operating Cash Flow-0.48
Balance Sheet
Tvardi Therapeutics has $30.81M in cash and marketable securities with $201.00K in debt, giving a net cash position of $30.61M billion.
Cash & Marketable Securities$30.81M
Total Debt$201.00K
Net Cash$30.61M
Net Cash Per Share$3.26
Tangible Book Value Per Share$2.78
Margins
Gross margin is 98.17%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin98.17%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Tvardi Therapeutics is $8.33, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$8.33
Price Target Upside175.83% Upside
Analyst ConsensusModerate Buy
Analyst Count7
Revenue Growth Forecast-53.67%
EPS Growth Forecast86.75%